C12N 2760/18341
Use of virus, viral particle or viral elements as a vector
C12N2760/18341 (Use of virus, viral particle or viral elements as a vector) appears on 20 US grants and 28 published applications in this corpus.
Search patents in C12N- Granted patents
- 20
- Published applications
- 28
- Assignees
- 15
- Inventors
- 37
- Latest grant
- 11 Jan 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 3 |
| 2005 | 0 | 3 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 1 | 1 |
| 2009 | 1 | 2 |
| 2010 | 2 | 2 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 3 | 2 |
| 2015 | 1 | 1 |
| 2016 | 2 | 1 |
| 2017 | 4 | 2 |
| 2018 | 1 | 3 |
| 2019 | 3 | 1 |
| 2020 | 0 | 3 |
| 2021 | 1 | 0 |
| 2022 | 1 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 1 |
| 2025 | 0 | 1 |
By publication year.
Subgroups
Granted patents
- C12N 2760/18343Viral genome or elements thereof as genetic vectorIndexing code20
- C12N 2760/18342Virus or viral particle as vehicleIndexing code0
- C12N 2760/18344Chimeric viral vector comprising heterologous viral elements for production of another viralIndexing code0
- C12N 2760/18345Special targeting system for viral vectorsIndexing code0
Recent patents
- Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences11 Jan 2022US 11,220,718 B2Erasmus University Medical Center Rotterdam
- Virus causing respiratory tract illness in susceptible mammals2 Nov 2021US 11,162,148 B2Erasmus University Medical Center Rotterdam
- Virus causing respiratory tract illness in susceptible mammals31 Dec 2019US 10,519,517 B2Erasmus University Medical Center
- Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences14 May 2019US 10,287,640 B2Erasmus University Medical Center Rotterdam
- Virus causing respiratory tract illness in susceptible mammals1 Jan 2019US 10,167,524 B2Erasmus University Medical Center Rotterdam
- Pan-pneumovirus vaccine compositions and methods of use thereof22 May 2025US 2025/0161429 A1University of Georgia Research Foundation, Inc.
- Human metapneumovirus viral vector-based vaccines19 Dec 2024US 2024/0415952 A1Sanofi Pasteur Limited
- Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences24 Dec 2020US 2020/0399718 A1Erasmus University Medical Center Rotterdam
- Virus causing respiratory tract illness in susceptible mammals7 May 2020US 2020/0140964 A1Erasmus University Medical Center Rotterdam
- Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences23 Jan 2020US 2020/0024672 A1Erasmus University Medical Center Rotterdam
Most cited
By later US patents
- Metapneumovirus strains and their use in vaccine formulations and sequences74US 8,722,341 B2MedImmune Vaccines, Inc. · 2014
- Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences35US 7,531,342 B2MedImmune, LLC · 2009
- Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences30US 7,449,324 B2MedImmune, LLC · 2008
- Virus causing respiratory tract illness in susceptible mammals29US 8,927,206 B2ViroNovative BV · 2015
- Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus27US 7,704,720 B2MedImmune, LLC · 2010